Consumer medicine information

Dutatam 500/400

Dutasteride; Tamsulosin hydrochloride

BRAND INFORMATION

Brand name

Dutatam 500/400

Active ingredient

Dutasteride; Tamsulosin hydrochloride

Schedule

SUMMARY CMI

DUTATAM 500/400

Consumer Medicine Information (CMI) summary

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist.

1. Why am I using DUTATAM 500/400?

DUTATAM 500/400 contains the active ingredients dutasteride and tamsulosin hydrochloride. DUTATAM 500/400 is used to treat benign prostatic hyperplasia (BPH).

For more information, see Section 1 Why am I using DUTATAM 500/400? in the full CMI.

2. What should I know before I use DUTATAM 500/400?

Do not use if you have ever had an allergic reaction to dutasteride, tamsulosin hydrochloride, any other 5 alpha reductase inhibitors or any of the ingredients listed at the end of the CMI.

Talk to your doctor if you have any other medical conditions or take any other medicines. Talk to your doctor if your partner is pregnant or plans to become pregnant or is breastfeeding.

For more information, see Section 2. What should I know before I use DUTATAM 500/400? in the full CMI.

3. What if I am taking other medicines?

Some medicines may interfere with DUTATAM 500/400 and affect how it works.

A list of these medicines is in Section 3. What if I am taking other medicines? in the full CMI.

4. How do I use DUTATAM 500/400?

The usual dose is one capsule once per day.
Take your medicine approximately 30 minutes after the same meal each day. Do not take DUTATAM 500/400 on an empty stomach.

More instructions can be found in Section 4. How do I use DUTATAM 500/400? in the full CMI.

5. What should I know while using DUTATAM 500/400?

Things you should do	Remind any doctor, dentist or pharmacist you visit that you are using DUTATAM 500/400. If you are having a blood test remind your doctor that you are taking DUTATAM 500/400. If you are having cataract surgery, tell your surgeon that you are taking DUTATAM 500/400.
Things you should not do	Do not stop using this medicine suddenly or change the dose. Do not donate blood whilst taking DUTATAM 500/400 or for 6 months after stopping treatment
Driving or using machines	Do not drive or operate machinery until you know how this medicine affects you. DUTATAM 500/400 can cause dizziness, light-headedness and potential fainting due to a sudden drop in blood pressure upon standing up (orthostatic hypotension).
Looking after your medicine	Store your capsules in the bottle until it is time to take them. Store the capsules below 25°C.

For more information, see Section 5. What should I know while using DUTATAM 500/400? in the full CMI.

6. Are there any side effects?

Less serious side effects include impotence (an inability to maintain an erection), decrease in sex drive, difficulty with ejaculation, dizziness, insomnia, fast heart beat, constipation, diarrhoea, vomiting, weakness, itchy, blocked or runny nose, hair loss or hair growth. Serious side effects are serious skin reactions, low blood pressure on standing, testicular pain and testicular swelling, prolonged painful erections, breast swelling or tenderness, and allergic reactions (wheezing, swelling of the lips/mouth, difficulty in breathing, lumpy rash (hives) or fainting). For more information, including what to do if you have any side effects, see Section 6. Are there any side effects? in the full CMI.

FULL CMI

DUTATAM 500/400

Active ingredient(s): Dutasteride 500 micrograms and tamsulosin hydrochloride 400 micrograms

Consumer Medicine Information (CMI)

This leaflet provides important information about using DUTATAM 500/400. You should also speak to your doctor or pharmacist if you would like further information or if you have any concerns or questions about using DUTATAM 500/400.

Where to find information in this leaflet:

1. Why am I using DUTATAM 500/400?
2. What should I know before I use DUTATAM 500/400?
3. What if I am taking other medicines?
4. How do I use DUTATAM 500/400?
5. What should I know while using DUTATAM 500/400?
6. Are there any side effects?
7. Product details

1. Why am I using DUTATAM 500/400?

DUTATAM 500/400 contains the active ingredient dutasteride and tamsulosin hydrochloride.

Dutasteride belongs to a group of medicines called 5-alpha reductase enzyme inhibitors and tamsulosin hydrochloride belongs to a group of medicines called alpha-blockers.

DUTATAM 500/400 is used to treat men with benign prostatic hyperplasia (BPH).

BPH is a non-cancerous enlargement of the prostate gland which is located at the lower portion of the urinary bladder surrounding the urethra (urine carrying tube). In men with BPH, the prostate gland becomes large enough to squeeze the urine tube running through it. If this tube is squeezed it narrows, making it more difficult to pass urine and you may have some or all of the following symptoms.

difficulty in starting to urinate
an interrupted, weak urinary stream
more frequent urination, especially at night
feeling that you need to urinate right away
leaking or dribbling
a feeling that you cannot empty your bladder completely

As the disease progresses, untreated BPH can lead to an increased risk of complete blockage of urine flow (acute urinary retention) and/or the need for surgery.

Prostate growth is caused by a hormone in the blood called dihydrotestosterone (DHT). The dutasteride component of DUTATAM 500/400 lowers DHT production in the body, leading to shrinkage of the enlarged prostate in most men. The tamsulosin hydrochloride component of DUTATAM 500/400 acts by relaxing the smooth muscle in your prostate gland, making it easier to pass urine.

Just as your prostate became large over a long period of time, reducing the size of your prostate and improving your symptoms may take time.

Your doctor may have prescribed DUTATAM 500/400 for another reason. Ask your doctor if you are unsure why DUTATAM 500/400 was prescribed for you.

DUTATAM 500/400 is not addictive.

2. What should I know before I use DUTATAM 500/400?

Warnings

Do not use DUTATAM 500/400 if:

you are allergic to dutasteride, tamsulosin, or any of the ingredients listed at the end of this leaflet. Always check the ingredients to make sure you can use this medicine.
you are allergic to any other 5 alpha reductase enzyme inhibitors
you are a woman or child.
you have a history of a sudden drop in blood pressure upon standing up (known as orthostatic hypotension)
you have severe liver or kidney disease
you are taking other medications that relax the smooth muscle of your blood vessels (e.g. Flomaxtra, Minipress)
the expiry date (EXP) printed on the pack has passed
the packaging is torn or shows signs of tampering

Check with your doctor if you:

have any other medical conditions
- suffer from any liver or kidney conditions
- are going to have cataract surgery
- are taking any medicines to lower your blood pressure (alpha blocker medicines that relax the smooth muscles within blood vessels)
- are taking an antifungal medicine (e.g. ketoconazole)
- you have an allergy to Sulphur
- take any medicines for any other condition

During treatment, you may be at risk of developing certain side effects. It is important you understand these risks and how to monitor for them. See additional information under Section 6. Are there any side effects?

Pregnancy and breastfeeding

Check with your doctor if your partner is a pregnant or intend to become pregnant or is breast feeding.

Women who are pregnant or may be pregnant, and children, must avoid handling punctured or leaking capsules. If skin contact occurs wash the area immediately with soap and water.

If dutasteride is absorbed through the skin by a woman who is pregnant with a male baby, it may cause the male baby to be born with abnormalities of the genital organs.

Dutasteride has been found in the semen of men taking dutasteride. If your partner is or may be pregnant, you must avoid exposing her to your semen as dutasteride may affect the normal development of a male baby. You must use a barrier form of contraception.

3. What if I am taking other medicines?

Tell your doctor or pharmacist if you are taking any other medicines, including any medicines, vitamins or supplements that you buy without a prescription from your pharmacy, supermarket or health food shop.

Tell your doctor or pharmacist if you are allergic to any foods, dyes, preservatives or any other medicines.

Some medicines may interfere with DUTATAM 500/400 and affect how it works.

long-term combination of dutasteride with medicines that are potent inhibitors of the enzyme CYP3A4 (e.g. ritonavir, indinavir, nefazodone, itraconazole, ketoconazole) may increase the concentration of dutasteride in the blood
antifungal medicines such as ketoconazole can lead to an increase in the concentration of tamsulosin hydrochloride in the blood
antidepressants known as selective serotonin reuptake inhibitors (e.g. paroxetine) can lead to an increase in the concentration of tamsulosin hydrochloride in the blood

Check with your doctor or pharmacist if you are not sure about what medicines, vitamins or supplements you are taking and if these affect DUTATAM 500/400.

4. How do I use DUTATAM 500/400?

How much to take

The usual dose is one capsule daily.
Follow the instructions provided and use DUTATAM 500/400 until your doctor tells you to stop.

When to take DUTATAM 500/400

DUTATAM 500/400 should be taken approximately 30 minutes after the same meal each day. Do not take this medicine on an empty stomach.
Swallow your capsule whole with some water.
Do not crush or chew the capsules. The contents of the capsule may make your mouth or throat sore.

If you forget to take DUTATAM 500/400

DUTATAM 500/400 should be taken at the same time each day.

If you forget to take DUTATAM 500/400 skip the dose you missed and take your next dose when you are meant to.

Do not take a double dose to make up for the dose you missed.

If you use too much DUTATAM 500/400

If you think that you have used too much DUTATAM 500/400, you may need urgent medical attention.

You should immediately:

phone the Poisons Information Centre
(by calling 13 11 26), or
contact your doctor, or
go to the Emergency Department at your nearest hospital.

You should do this even if there are no signs of discomfort or poisoning.

5. What should I know while using DUTATAM 500/400?

Things you should do

Tell your doctor if, you:

have not taken DUTATAM 500/400 as directed.
are having a blood test, tell your doctor you are taking DUTATAM 500/400 as this medicine decreases your prostate-specific antigen (PSA) levels.
The PSA test helps your doctor to tell if you have prostate disease, including prostate cancer. If you have a higher than normal amount of PSA in your blood it could mean that you have a higher risk of prostate cancer. Men taking DUTATAM 500/400 should have their PSA measured 6 months after starting treatment and then regularly after that. You could still be at risk for prostate cancer even though your PSA is lower. Your doctor can still use PSA to help detect prostate cancer, by comparing your test results each time you have a PSA test.

Remind any doctor, dentist or pharmacist you visit that you are taking DUTATAM 500/400.

Things to be careful of

If you are having a cataract operation and are taking or have previously taken DUTATAM 500/400, the pupil may dilate poorly and the iris (the coloured part of the eye) may become floppy during the operation (floppy iris syndrome). This can be managed if your surgeon knows that you are taking DUTATAM 500/400 before you have the operation. If you are going to have eye surgery tell your surgeon that you are taking or have taken DUTATAM 500/400.

In a clinical study of men at increased risk of developing prostate cancer, a serious form of prostate cancer was reported more often in men taking DUTATAM 500/400 than men who did not take DUTATAM 500/400. The reasons for this is currently unknown but may be due to the design of the clinical study.

Be careful if you are switching from another tamsulosin containing medicine to DUTATAM 500/400 as you may experience dizziness or light headedness when standing up.

If you feel dizzy or lightheaded at any time whilst taking DUTATAM 500/400, sit or lie down until the symptoms pass.

Things you should not do

Do not stop using this medicine suddenly or change the dose.
Some men notice an early improvement in their symptoms however others may need to continue treatment for 3 to 6 months to see if DUTATAM 500/400 works for them.
Continue to take this medicine as your symptoms improve.
If you do not take your medicine as directed it may interfere with your doctor's ability to monitor your PSA levels.
Do not donate blood whilst taking DUTATAM 500/400 or for 6 months after you stop treatment.
Do not give this medicine to anyone else even if they have similar symptoms to you.
Do not use this medicine to treat any other complaints.

Driving or using machines

Be careful before you drive or use any machines or tools until you know how DUTATAM 500/400 affects you.

DUTATAM 500/400 some people to experience dizziness or light headedness.

Looking after your medicine

Keep your tablets in in the original pack until it is time to take them
Keep DUTATAM 500/400 in a cool, dry place where it stays below 25°C.

Follow the instructions on the bottle on how to take care of your medicine properly.

Store it in a cool dry place (below 25°C) away from moisture, heat or sunlight; for example, do not store it:

in the bathroom or near a sink, or
in the car or on window sills.

Store your capsules in the bottle until it is time to take them.

Keep it where young children cannot reach it.

Getting rid of any unwanted medicine

If you no longer need to use this medicine or it is out of date, take it to any pharmacy for safe disposal.

Do not use this medicine after the expiry date.

6. Are there any side effects?

All medicines can have side effects. If you do experience any side effects, most of them are minor and temporary. However, some side effects may need medical attention.

In clinical studies where patients were taking both the individual components of DUTATAM 500/400, the rate of heart failure (meaning your heart does not pump blood as well as it should) was higher than in patients taking the individual components alone. However, this was seen in less than 1% of patients.

If you are taking DUTATAM 500/400, talk to your doctor about this and other possible side effects.

See the information below and, if you need to, ask your doctor or pharmacist if you have any further questions about side effects.

Less serious side effects

Less serious side effects

What to do

impotence (inability to achieve or maintain an erection)
decrease in libido (sex drive)
difficulty with ejaculation or retrograde ejaculation (where the ejaculate goes back into the bladder instead of being squirted out)
decrease in semen volume
difficulty in sleeping (insomnia)
dizziness
constipation
diarrhoea
vomiting
fast heart beat
weakness or loss of strength
hair loss (usually from the body) or hair growth
fainting
changes in your mood, feeling depressed
itchy, blocked or runny nose
changes in your vision
nose bleeds
dry mouth

Speak to your doctor if you have any of these less serious side effects and they worry you.

Serious side effects

Serious side effects

What to do

allergic reaction – signs include wheezing, difficulty breathing, swelling of the lips or mouth, a rash or hives on the skin and fainting
breast swelling or tenderness. If this becomes troublesome or you notice breast lumps or nipple discharge talk to your doctor about these changes as they could be signs of a serious condition such as breast cancer.
serious skin reactions with a widespread rash, blisters and peeling skin particularly around the mouth, nose, eyes and genitals (such as Stevens-Johnson syndrome)
testicular pain and/or swelling
low blood pressure upon standing up (orthostatic hypotension). Take care when moving from a lying or sitting position to a standing position
prolonged erection unrelated to sexual activity

Call your doctor straight away, or go straight to the Emergency Department at your nearest hospital if you notice any of these serious side effects.

Tell your doctor or pharmacist if you notice anything else that may be making you feel unwell.

Other side effects not listed here may occur in some people.

Reporting side effects

After you have received medical advice for any side effects you experience, you can report side effects to the Therapeutic Goods Administration online at www.tga.gov.au/safety/reporting-problems. By reporting side effects, you can help provide more information on the safety of this medicine.

Always make sure you speak to your doctor or pharmacist before you decide to stop taking any of your medicines.

7. Product details

This medicine is only available with a doctor's prescription.

What DUTATAM 500/400 contains

Active ingredient (main ingredient)	dutasteride and tamsulosin hydrochloride.
Other ingredients (inactive ingredients)	butylated hydroxytoluene glyceryl caprylate gelatin glycerol titanium dioxide medium chain triglycerides isopropyl alcohol microcrystalline cellulose methacrylic acid - ethyl acrylate copolymer (1:1) talc triacetin iron oxide yellow hypromellose carrageenan potassium acetate TekPrint SW-9008 Black Ink.

Do not take this medicine if you are allergic to any of these ingredients.

What DUTATAM 500/400 looks like?

DUTATAM 500/400 modified release capsules are two piece, hard shell, size 00 capsules with an opaque yellow cap printed '640' with black ink and opaque white body, containing white to off DUTATAM 500/400 CAPSULES 4 white pellets and one white to off white soft gelatin capsule. (Aust R 414643).

DUTATAM 500/400 capsules are available in HDPE bottles with a child-resistant screw cap of 30 capsules.

Who distributes DUTATAM 500/400?

MedTAS Pty Ltd
5B 9-13 Redmyre Road
Strathfield
Sydney NSW 2135
Australia
Email: [email protected]

Published by MIMS November 2024

BRAND INFORMATION

Brand name

Dutatam 500/400

Active ingredient

Dutasteride; Tamsulosin hydrochloride

Schedule

1 Name of Medicine

Dutasteride/tamsulosin hydrochloride.

2 Qualitative and Quantitative Composition

Each capsule contains dutasteride 500 microgram and tamsulosin hydrochloride 400 microgram.
For the full list of excipients, see Section 6.1 List of Excipients.

3 Pharmaceutical Form

Dutatam 500/400 modified release capsules.

Two piece, hard shell, size 00 capsules with an opaque yellow cap printed '640' with black ink and opaque white body, containing white to off white pellets and one white to off white soft gelatin capsule.

4 Clinical Particulars

4.1 Therapeutic Indications

Dutatam 500/400 is indicated for the management of moderate to severe symptomatic benign prostatic hyperplasia (BPH).

4.2 Dose and Method of Administration

Dutatam 500/400 must be taken approximately 30 minutes after the same meal each day. Patients should be advised that Dutatam 500/400 should not be taken on an empty stomach as this may increase the potential for cardiovascular related adverse events such as orthostatic hypotension.
For advice on switching from tamsulosin monotherapy to Dutatam 500/400 combination therapy, please read the information under Section 5.1 Pharmacodynamic Properties.

Populations.

Adult males (including elderly).

The recommended dose of Dutatam 500/400 is one capsule (500 microgram dutasteride/400 microgram tamsulosin) taken orally approximately 30 minutes after the same meal each day (see Section 5.2 Pharmacokinetic Properties, Absorption).
The capsules should be swallowed whole and not chewed or opened. Contact with the contents of the dutasteride capsule contained within the hard-shell capsule may result in irritation of the oropharyngeal mucosa.

Renal impairment.

The effect of renal impairment on dutasteride/tamsulosin hydrochloride pharmacokinetics has not been studied. However, no adjustment in dosage is anticipated for patients with renal impairment (see Section 5.2 Pharmacokinetic Properties, Renal impairment).
Dutatam 500/400 is contraindicated in patients with severe renal impairment (see Section 4.3 Contraindications).

Hepatic impairment.

The effect of hepatic impairment on dutasteride/tamsulosin hydrochloride pharmacokinetics has not been studied (see Section 4.4 Special Warnings and Precautions for Use; Section 5.2 Pharmacokinetic Properties, Hepatic impairment). Dutatam 500/400 is contraindicated in patients with severe hepatic impairment (see Section 4.3 Contraindications).

4.3 Contraindications

Dutatam 500/400 is contraindicated in:
patients with known hypersensitivity to dutasteride, other 5α-reductase inhibitors, tamsulosin hydrochloride or any component of the preparation;
women and children (see Section 4.6 Fertility, Pregnancy and Lactation);
patients with a history of orthostatic hypotension;
patients with severe hepatic impairment (Child-Pugh scores > 9);
patients with severe renal impairment (creatinine clearance less than 10 mL/min);
combination with another α₁-adrenergic blocker.

4.4 Special Warnings and Precautions for Use

Dutatam 500/400 should be prescribed after careful benefit risk assessment and after consideration of alternative treatment options including monotherapies.
Dutatam 500/400 must be taken approximately 30 minutes after the same meal each day (see Section 4.2 Dose and Method of Administration). Taking Dutatam 500/400 on an empty stomach may increase the potential for cardiovascular related adverse events such as orthostatic hypotension.

Prostate cancer.

In a 4-year study of over 8000 men aged 50 to 75, with a prior negative biopsy for prostate cancer and baseline PSA between 2.5 nanogram/mL and 10.0 nanogram/mL (the REDUCE study), 1517 men were diagnosed with prostate cancer. There was a higher incidence of Gleason 8 to 10 prostate cancers in the dutasteride group (n = 29, 0.9%) compared to the placebo group (n = 19, 0.6%). There was no increased incidence in Gleason 5-6 or 7-10 prostate cancers. No causal relationship between dutasteride and high grade prostate cancer has been established. The clinical significance of the numerical imbalance is unknown. Men taking dutasteride should be regularly evaluated for prostate cancer risk including PSA testing (see Section 5.1 Pharmacodynamic Properties, Clinical trials).
In an additional 2-year follow-up study of the original patients from the dutasteride study (REDUCE), a low rate of new prostate cancers were diagnosed (dutasteride [n = 14, 1.2%] and placebo [n = 7, 0.7%]), with no new identified cases of Gleason 8-10 prostate cancers except in one case from the former dutasteride treatment group where local pathology review reported a Gleason 8 case and central pathology review was not available. Dutasteride treatment was not provided during the follow-up study period but patients from either treatment arm were able to take 5-ARI therapy if prescribed.

Effects on prostate specific antigen (PSA) and prostate cancer detection.

Digital rectal examination, as well as other evaluations for prostate cancer, should be performed on patients with BPH prior to initiating therapy with Dutatam 500/400 and periodically thereafter.
PSA concentration is an important component of the screening process to detect prostate cancer. Dutasteride causes a decrease in mean serum PSA levels by approximately 50% after 6 months of treatment.
Patients receiving Dutatam 500/400 should have a new PSA baseline established after 6 months of treatment with dutasteride. It is recommended to monitor PSA values regularly thereafter. Any confirmed increase from lowest PSA level while on Dutatam 500/400 may signal the presence of prostate cancer (particularly high grade cancer) or non-compliance to therapy with Dutatam 500/400 and should be carefully evaluated, even if those values are still within the normal range for men not taking a 5-ARI (see Section 5.1 Pharmacodynamic Properties, Clinical trials). In the interpretation of a PSA value for a patient taking dutasteride, previous PSA values should be sought for comparison.
Treatment with Dutatam 500/400 does not interfere with the use of PSA as a tool to assist in the diagnosis of prostate cancer after a new baseline has been established.
Total serum PSA levels return to baseline within 6 months of discontinuing treatment.
The ratio of free to total PSA remains constant even under the influence of dutasteride. If clinicians elect to use percent-free PSA as an aid in the detection of prostate cancer in men undergoing Dutatam 500/400 therapy, no adjustment to its value is necessary.

Cardiovascular adverse events.

In two 4-year clinical studies, the incidence of cardiac failure (a composite term of reported events, primarily cardiac failure and congestive cardiac failure) was higher among subjects taking the combination of dutasteride and an alpha blocker, (primarily tamsulosin, alfuzosin, doxazosin and terazosin) than it was among subjects not taking the combination. In these two trials, the incidence of cardiac failure was ≤ 1%. The reason for the imbalance of cardiac failure in the two trials is not known. No imbalance was observed in the incidence of cardiovascular adverse events overall in either trial. No causal relationship between dutasteride (alone or in combination with an alpha blocker) and cardiac failure has been established (see Section 5.1 Pharmacodynamic Properties, Clinical trials).
In a meta-analysis of 12-randomised, placebo- or comparator-controlled clinical studies (n = 18,802) that evaluated the risks of developing cardiovascular adverse events from the use of dutasteride (by comparison with controls), no consistent statistically significant increase in the risk of heart failure (RR 1.05; 95% CI 0.71, 1.57), acute myocardial infarction (RR 1.00; 95% CI 0.77, 1.30) or stroke (RR 1.20; 95% CI 0.88, 1.64) were found. The relationship between dutasteride use and the cardiovascular adverse events heart failure, acute myocardial infarction and stroke is unclear.

Breast cancer.

There have been reports of male breast cancer reported in men taking dutasteride in clinical trials and during the post-marketing period. However, epidemiological studies showed no statistically significant increase in the risk of developing male breast cancer with the use of 5-ARIs (see Section 5.1 Pharmacodynamic Properties, Clinical trials). Prescribers should instruct their patients to promptly report any changes in their breast tissue such as lumps or nipple discharge. It is not clear if there is a causal relationship between the occurrence of male breast cancer and long term use of dutasteride.

Hypotension.

As with other α₁-adrenergic blockers, orthostatic hypotension can occur in patients treated with tamsulosin, which in rare cases can result in syncope.
There have been no studies to investigate the effect of dutasteride/tamsulosin hydrochloride on the ability to perform tasks that require judgement, motor or cognitive skills. However, patients should be informed about the possible occurrence of symptoms related to orthostatic hypotension such as dizziness when taking Dutatam 500/400.
Patients beginning treatment with Dutatam 500/400 should be cautioned to sit or lie down at the first signs of orthostatic hypotension (dizziness and vertigo) until the symptoms have resolved and to report such symptoms without delay to their doctor. They should also be cautioned to avoid situations where injury could result should these symptoms occur.
Patients switching from the current Australian tamsulosin product should be advised of the differences between this product and Dutatam 500/400 (see Section 5.2 Pharmacokinetic Properties) and the potential for orthostatic hypotension (particularly if Dutatam 500/400 is taken on an empty stomach). Patients should be advised to take Dutatam 500/400 approximately 30 minutes after the same meal each day and never on an empty stomach, as well as the need to maintain vigilance for signs of dizziness and vertigo.
Caution is advised when alpha adrenergic blocking agents including tamsulosin are co-administered with phosphodiesterase type 5 inhibitor (PDE5) inhibitors. Alpha adrenergic blockers and PDE5 inhibitors are both vasodilators that can lower blood pressure. Concomitant use of these two drug classes can potentially cause symptomatic hypotension (see Section 4.5 Interactions with Other Medicines and Other Forms of Interactions).

Blood donation.

Men being treated with any dutasteride-containing products, including Dutatam 500/400, should not donate blood until at least 6 months have passed following their last dose. The purpose of this deferred period is to prevent administration of dutasteride to a pregnant female transfusion recipient.

Intraoperative floppy iris syndrome.

Intraoperative floppy iris syndrome (IFIS, a variant of small pupil syndrome) has been observed during cataract surgery in some patients treated with α₁-adrenergic blockers, including tamsulosin. This syndrome is characterised by the combination of a flaccid iris that billows as a result of intra-operative irrigation currents, prolapse of the iris toward the phacoemulsification incisions, and progressive intra-operative miosis despite pre-operative dilation with standard mydriatic drugs. IFIS may increase the risk of eye complications during and after operation.
During pre-operative assessment, cataract surgeons and ophthalmic teams should consider whether patients scheduled for cataract surgery are being or have been treated with Dutatam 500/400 in order to ensure that appropriate measures will be in place to manage IFIS if it occurs during surgery.
Discontinuing tamsulosin 1-2 weeks prior to cataract surgery is anecdotally considered helpful, but the benefit and duration of stopping of therapy prior to cataract surgery has not yet been established.

Leaking capsules.

Dutatam 500/400 is absorbed through the skin, therefore women and children must avoid contact with leaking capsules. If contact is made with leaking capsules the contact area should be washed immediately with soap and water (see Section 4.6 Fertility, Pregnancy and Lactation, Use in pregnancy, Use in lactation).

Inhibitors of CYP3A4 and CYP2D6.

Concomitant administration of tamsulosin hydrochloride with strong inhibitors of CYP3A4 (e.g. ketoconazole), or to a lesser extent, with strong inhibitors of CYP2D6 (e.g. paroxetine) can increase tamsulosin exposure (see Section 4.5 Interactions with Other Medicines and Other Forms of Interactions). Tamsulosin hydrochloride is therefore not recommended in patients taking a strong CYP3A4 inhibitor and should be used with caution in patients taking a moderate CYP3A4 inhibitor (e.g. erythromycin), a strong or moderate CYP2D6 inhibitor, a combination of both CYP3A4 and CYP2D6 inhibitors, or in patients known to be poor metabolisers of CYP2D6 (see Section 4.5 Interactions with Other Medicines and Other Forms of Interactions).

Sulfur allergy.

A causal relationship between tamsulosin and sulfur allergy has not been established, however there is a theoretical risk of an allergic reaction when tamsulosin is taken by patients with a history of sulfur allergy. If a patient reports a serious or life threatening sulfur allergy, caution is warranted when administering Dutatam 500/400.

Use in hepatic impairment.

The effect of hepatic impairment on dutasteride pharmacokinetics has not been studied. Because dutasteride is extensively metabolised and has a half-life of 3 to 5 weeks, caution should be used in the administration of dutasteride to patients with liver disease (see Section 4.2 Dose and Method of Administration; Section 5.2 Pharmacokinetic Properties).
Dutatam 500/400 is contraindicated in patients with severe hepatic impairment.

Use in renal impairment.

Severe renal impairment, with creatinine clearance of less than 10 mL/min, is a contraindication, as these patients have not been studied.

Use in the elderly.

See Section 4.4 Special Warnings and Precautions for Use.

Paediatric use.

The use of dutasteride/tamsulosin hydrochloride is contraindicated in children. Dutasteride/tamsulosin hydrochloride has not been studied in children.

Effects on laboratory tests.

No data available.

4.5 Interactions with Other Medicines and Other Forms of Interactions

There have been no drug interaction studies for dutasteride/tamsulosin hydrochloride. The following statements reflect the information available on the individual components.

Interactions of dutasteride and tamsulosin with cytochrome P450 inhibitors.

Dutasteride. In vitro drug metabolism studies show that dutasteride is metabolised by human cytochrome P450 isoenzyme CYP3A4. Therefore, blood concentrations of dutasteride may increase in the presence of inhibitors of CYP3A4.
Long-term combination of dutasteride with drugs that are potent inhibitors of the enzyme CYP3A4 (e.g. ritonavir, indinavir, nefazodone, itraconazole, ketoconazole administered orally) may increase serum concentrations of dutasteride. Further inhibition of 5α-reductase at increased dutasteride exposure, is not likely. However, a reduction of the dutasteride dosing frequency can be considered if side effects are noted. It should be noted that in the case of enzyme inhibition, the long half-life may be further prolonged and it can take more than 6 months of concurrent therapy before a new steady state is reached.
Phase II data showed a decrease in clearance of dutasteride when co-administered with the CYP3A4 inhibitors verapamil (37%) and diltiazem (44%). In contrast no decrease in clearance was seen when amlodipine, another calcium channel antagonist, was co-administered with dutasteride. A decrease in clearance and subsequent increase in exposure to dutasteride, in the presence of CYP3A4 inhibitors, is unlikely to be clinically significant due to the wide margin of safety (up to 10-times the recommended dose has been given to patients for up to six months), therefore no dose adjustment is necessary.
In vitro, dutasteride is not metabolised by human cytochrome P450 isoenzymes CYP1A2, CY2A6, CYP2E1, CYP2C8, CYP2C9, CYP2C19, CYP2B6 and CYP2D6.
Dutasteride neither inhibits human cytochrome P450 drug-metabolising enzymes in vitro nor induces cytochrome P450 isoenzymes CYP1A, CYP2B, and CYP3A in rats and dogs in vivo.
Tamsulosin.

Strong and moderate inhibitor of CYP3A4 or CYP2D6.

Tamsulosin is extensively metabolised, mainly by CYP3A4 or CYP2D6.
Concomitant treatment of tamsulosin hydrochloride and ketoconazole (a strong inhibitor of CYP3A4) resulted in an increase in the C_max and AUC of tamsulosin hydrochloride. The effects of concomitant administration of a moderate CYP3A4 inhibitor (e.g. erythromycin) on the pharmacokinetics of tamsulosin have not been evaluated. Concomitant treatment with paroxetine (a strong inhibitor of CYP2D6) has also resulted in an increase of the C_max and AUC of tamsulosin. A similar increase in exposure is expected in CYP2D6 poor metabolisers as compared to extensive metabolisers when co-administered with a strong CYP3A4 inhibitor. The effects of concomitant administration of a moderate CYP2D6 inhibitor (e.g. terbinafine) on the pharmacokinetics of tamsulosin have not been evaluated. The effects of concomitant administration of both a CYP3A4 and a CYP2D6 inhibitor with tamsulosin have not been evaluated. However, there is a potential for significant increase in tamsulosin exposure when tamsulosin 0.4 mg is co-administered with a combination of both CYP3A4 and CYP2D6 inhibitors. Tamsulosin hydrochloride is not recommended in patients taking a strong CYP3A4 inhibitor and should be used with caution in patients taking a moderate CYP3A4 inhibitor (e.g. erythromycin), a strong or moderate CYP2D6 inhibitor, a combination of both CYP3A4 and CYP2D6 inhibitors, or in patients known to be poor metabolisers of CYP2D6.

Interactions of dutasteride and tamsulosin with particular drugs or classes of drugs.

Cimetidine. Concomitant administration of tamsulosin hydrochloride (400 microgram) and cimetidine (400 mg every 6 hours for 6 days) resulted in a decrease in the clearance (26%) and an increase in the AUC (44%) of tamsulosin hydrochloride. Caution should be used when dutasteride/tamsulosin is used in combination with cimetidine.
Alpha-adrenergic antagonists. There is a risk of additive hypotensive effects when tamsulosin hydrochloride is co-administered with drugs which can reduce blood pressure, including anaesthetic agents and other α₁-adrenergic blockers. Concurrent administration of Dutatam 500/400 and other drugs containing α₁-adrenergic blockers is therefore contraindicated (see Section 4.3 Contraindications).
PDE5 inhibitors. Caution is advised when alpha-adrenergic antagonists, including tamsulosin containing products such as Dutatam 500/400, are co-administered with PDE5 inhibitors. Alpha-adrenergic antagonists and PDE5 inhibitors are both vasodilators that can lower blood pressure. Concomitant use of these 2 drug classes can potentially cause symptomatic hypotension.
Warfarin.

Dutasteride.

In vitro studies demonstrate that dutasteride does not displace warfarin. No clinically significant interactions have been observed following concomitant administration of dutasteride and tamsulosin.

Tamsulosin.

A definitive drug-drug interaction study between tamsulosin hydrochloride and warfarin has not been conducted. Results from limited in vitro and in vivo studies are inconclusive. Caution should be exercised with concomitant administration of warfarin and tamsulosin hydrochloride.
Nifedipine, atenolol, enalapril.

Tamsulosin.

In three studies, no interactions were seen when tamsulosin (400 microgram for seven days followed by 800 microgram for 7 days) was given concomitantly with atenolol, enalapril or nifedipine for 3 months; therefore, no dose adjustments are necessary when these drugs are co-administered with Dutatam 500/400.
Digoxin and theophylline.

Dutasteride.

Dutasteride does not alter the steady-state pharmacokinetics of digoxin.

Tamsulosin.

Dosage adjustments are not necessary when tamsulosin is administered concomitantly with digoxin.
Concomitant administration of tamsulosin hydrochloride (400 microgram/day for two days, followed by 800 microgram/day for five to eight days) and a single i.v. dose of theophylline (5 mg/kg) resulted in no change in the pharmacokinetics of theophylline; therefore, no dose adjustment is necessary.
Furosemide.

Tamsulosin.

Concomitant administration of tamsulosin hydrochloride (800 microgram/day) and a single i.v. dose of furosemide (20 mg) produced an 11% to 12% reduction in the C_max and AUC of tamsulosin hydrochloride, however these changes are expected to be clinically insignificant and no dose adjustment is necessary.
Calcium channel blockers.

Dutasteride.

Co-administration of verapamil or diltiazem decreases dutasteride clearance and leads to increased exposure to dutasteride. However, the change in dutasteride exposure is not considered clinically significant. No dosage adjustment of dutasteride is recommended.
Cholestyramine.

Dutasteride.

Administration of a single 500 microgram dose of dutasteride followed 1 hour later by a 12 g dose of cholestyramine does not affect the relative bioavailability of dutasteride.
Other products.

Dutasteride.

In vitro studies demonstrate that dutasteride does not displace acenocoumarol, phenprocoumon, diazepam, or phenytoin from plasma protein, nor do these model compounds displace dutasteride.
Although specific interaction studies were not performed with other compounds, approximately 90% of the subjects in large Phase III studies receiving dutasteride were taking other medications concomitantly. No clinically significant adverse interactions were observed in clinical trials when dutasteride was co-administered with anti-hyperlipidemics, angiotensin converting enzyme (ACE) inhibitors, beta-adrenergic blocking agents, calcium channel blockers, corticosteroids, diuretics, non-steroidal anti-inflammatory drugs (NSAIDs), phosphodiesterase Type V inhibitors, and quinolone antibiotics.
A drug interaction study with tamsulosin or terazosin administered in combination with dutasteride for two weeks showed no evidence of pharmacokinetic or pharmacodynamic interactions.
Tamsulosin binds extensively to plasma proteins and may displace other protein-bound drugs. Conclusive clinical trials data are not available.

4.6 Fertility, Pregnancy and Lactation

Effects on fertility.

There have been no studies to investigate the effect of dutasteride/tamsulosin hydrochloride on pregnancy, lactation and fertility. The following statements reflect the information available on the individual components.

Dutasteride.

No animal fertility studies have been conducted with co-administration of dutasteride and tamsulosin.
Treatment of sexually mature male rats with dutasteride at doses up to 500 mg/kg/day (110-fold the expected clinical exposure of parent drug) for up to 31 weeks resulted in dose- and time-dependant decreases in fertility, reduced cauda epididymal (absolute) sperm counts (at 50 and 500 mg/kg/day), reduced weights of the epididymis, prostate and seminal vesicles, and microscopic changes in the male reproductive organs. The fertility effects were reversed by recovery week 6 at all doses and sperm counts were normal at the end of a 14-week recovery period. The 5α-reductase-related changes consisted of cytoplasmic vacuolation of tubular epithelium in the epididymides and decreased cytoplasmic content of epithelium, consistent with decreased secretory activity in the prostate and seminal vesicles. The microscopic changes were no longer present at recovery week 14 in the low dose group and were partly recovered in the remaining treatment groups. Low levels of dutasteride were detected in the serum of untreated female rats mated to males dosed at 10 mg/kg/day and above for 29 weeks.
The effects of dutasteride 500 microgram/day on semen characteristics were evaluated in normal volunteers aged 18 to 52 (n = 27 dutasteride, n = 23 placebo) throughout 52 weeks of treatment and 24 weeks of post treatment follow-up. At 52 weeks, the mean percent reduction from baseline in total sperm count, semen volume, and sperm motility were 23%, 26%, and 18%, respectively, in the dutasteride group when adjusted for changes from baseline in the placebo group. Sperm concentration and sperm morphology were unaffected. After 24 weeks of follow-up, the mean percent change in total sperm count in the dutasteride group remained 23% lower than baseline. While mean values for all semen parameters at all time points remained within the normal ranges and did not meet predefined criteria for a clinically significant change (30%), two subjects in the dutasteride group had decreases in sperm count of greater than 90% from baseline at 52 weeks, with partial recovery at the 24-week follow-up. The clinical significance of dutasteride's effect on semen characteristics for an individual patient's fertility is not known.

Tamsulosin.

High doses of tamsulosin hydrochloride resulted in a reversible reduction in fertility in male rats considered possibly due to changes of semen content of impairment of ejaculation. Effects of tamsulosin hydrochloride on sperm counts or sperm function have not been evaluated.
(Category X)
Dutatam 500/400 is contraindicated for use in women.

Dutasteride.

As with other 5α-reductase inhibitors, dutasteride inhibits the conversion of testosterone to dihydrotestosterone and may, if administered to a woman carrying a male foetus, inhibit the development of the external genitalia of the foetus. Small amounts of dutasteride have been recovered from the semen in subjects receiving dutasteride. Based on studies in animals, it is unlikely that a male foetus will be adversely affected if his mother is exposed to the semen of a patient being treated with dutasteride (the risk of which is greatest during the first 16 weeks of pregnancy). However, as with all 5α-reductase inhibitors, when the patient's partner is or may potentially be pregnant it is recommended that the patient avoids exposure of his partner to semen by use of a condom.

Tamsulosin.

Administration of tamsulosin hydrochloride to pregnant female rats and rabbits at higher than the therapeutic dose showed no evidence of foetal harm.
Dutatam 500/400 is contraindicated for use in women.
It is not known whether dutasteride or tamsulosin are excreted in breast milk.

4.7 Effects on Ability to Drive and Use Machines

There have been no studies to investigate the effect of dutasteride/tamsulosin hydrochloride on the ability to perform tasks that require judgement, motor or cognitive skills. However, patients should be informed about the possible occurrence of symptoms related to orthostatic hypotension such as dizziness when taking Dutatam 500/400.

4.8 Adverse Effects (Undesirable Effects)

There have been no clinical trials conducted with dutasteride/tamsulosin hydrochloride; however, co-administration information for years 1 and 2 is available from the CombAT (Combination of Avodart and Tamsulosin) study, a comparison of dutasteride 500 microgram and tamsulosin 400 microgram once daily for four years as co-administration or as monotherapy.
Information on the adverse event profiles of the individual components (dutasteride and tamsulosin) is also provided.

Dutasteride and tamsulosin co-administration.

Clinical trial data. The following investigator-judged drug-related adverse events (with a cumulative incidence of greater than or equal to 1%) have been reported during the CombAT study.

Dutasteride monotherapy.

Clinical trial data. In three phase III placebo controlled studies of dutasteride treatment (n = 2167) compared to placebo (n = 2158), investigator-judged drug-related adverse events after one and two years of therapy were similar in type and frequency to those observed in the dutasteride monotherapy arm of the CombAT study (see Table 1).
No change in the adverse event profile was apparent over a further 2 years in an open-label extension phase of these studies.
Post marketing data. Adverse drug reactions are listed below by system organ class and frequency. Frequencies are defined as: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1000 to < 1/100), rare (≥ 1/10,000 to < 1/1000) and very rare (< 1/10,000) including isolated reports. Frequency categories determined from post-marketing data refer to reporting rate rather than true frequency.

Immune system disorders.

Very rare: allergic reactions, including rash, pruritus, urticaria, localised oedema, and angioedema.

Psychiatric disorders.

Very rare: depressed mood.

Skin and subcutaneous tissue disorders.

Rare: alopecia (primarily body hair loss), hypertrichosis.

Reproductive system and breast disorders.

Very rare: testicular pain and testicular swelling.

Tamsulosin monotherapy.

Clinical trial data and post marketing data.

Priapism.

Rarely, tamsulosin, like other α₁-antagonists, has been associated with priapism (persistent painful penile erection unrelated to sexual activity). Patients should be informed that this reaction is extremely rare, but if not brought to immediate medical attention, can lead to permanent erectile dysfunction.

Abnormal ejaculation.

Patients should also be advised on the potential for abnormal ejaculation, such as retrograde ejaculation, to occur upon commencement of tamsulosin treatment.
The adverse reactions and frequency categories below relating to tamsulosin monotherapy are based on information available in the public domain. In Table 2, common and uncommon reactions are consistent with those identified in a clinical trial setting and the frequency categories generally reflect incidence over placebo. Rare and very rare reactions are consistent with those identified from post marketing reports and the frequency categories reflect reporting rates.

During post marketing surveillance, reports of intraoperative floppy iris syndrome (IFIS), a variant of small pupil syndrome, during cataract surgery have been associated with α₁-adrenergic blocker therapy; including tamsulosin (see Section 4.4 Special Warnings and Precautions for Use). Infrequent reports of skin desquamation have also been received.

Post-marketing experience.

In addition, atrial fibrillation, arrhythmia, tachycardia, dyspnoea, epistaxis, vision blurred, visual impairment, erythema multiforme, dermatitis exfoliative and dry mouth have been reported in association with tamsulosin use.

Reporting suspected adverse effects.

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at www.tga.gov.au/reporting-problems.

4.9 Overdose

No data are available with regard to overdosage of dutasteride/tamsulosin hydrochloride. The following statements reflect the information available on the individual components.

Dutasteride.

In volunteer studies single doses of dutasteride up to 40 mg/day (80 times the therapeutic dose) for 7 days have been administered without significant safety concerns. In clinical studies doses of 5 mg daily have been administered to patients for 6 months with no additional adverse effects to those seen at therapeutic doses of 500 microgram.
There is no specific antidote for dutasteride therefore, in cases of suspected overdosage symptomatic and supportive treatment should be given as appropriate.

Tamsulosin.

In case of acute hypotension occurring after overdosage with tamsulosin hydrochloride cardiovascular support should be given. Restoration of blood pressure and normalization of heart rate may be accomplished by lying the patient down. If this is inadequate, administration of volume expanders and if necessary vasopressors should then be used and renal function should be monitored and supported as needed. Laboratory data indicate that tamsulosin hydrochloride is 94% to 99% protein bound; therefore, dialysis is unlikely to be of benefit in removing tamsulosin from the body.
For information on the management of overdose, contact the Poisons Information Centre on 13 11 26 (Australia).

5 Pharmacological Properties

5.1 Pharmacodynamic Properties

Mechanism of action.

Dutasteride-tamsulosin is a combination of two drugs with complementary mechanisms of action to improve symptoms in patients with benign prostatic hyperplasia (BPH): dutasteride, a dual 5α-reductase inhibitor (5-ARI) and tamsulosin hydrochloride, an antagonist of α_1a-adrenoreceptors.
Dutasteride inhibits both type 1 and type 2, 5α-reductase isoenzymes, which are responsible for the conversion of testosterone to 5α-dihydrotestosterone (DHT). DHT is the androgen primarily responsible for hyperplasia of glandular prostatic tissue.
Tamsulosin inhibits α_1a-adrenergic receptors in the stromal prostatic smooth muscle and bladder neck. Approximately 75% of the α₁-receptors in the prostate are of the α_1a subtype.
Pharmacodynamic effects. The pharmacodynamic effects of dutasteride-tamsulosin as a fixed dose combination would not be expected to be different from those of dutasteride and tamsulosin co-administered as separate components.

Dutasteride.

Dutasteride lowers DHT levels, reduces prostate volume, improves lower urinary tract symptoms and urine flow and reduces the risk of acute urinary retention (AUR) and BPH-related surgery.
The maximum effect of daily doses of dutasteride on the reduction on DHT is dose dependent and is observed within one to two weeks. After one week and two weeks of daily dosing of dutasteride 500 microgram, median serum DHT concentrations were reduced by 85% and 90%, respectively.
In BPH patients treated with 500 microgram of dutasteride daily, the median decrease in DHT was 94% at one year and 93% at two years, and the median increase in serum testosterone was 19% at both one and two years. This is an expected consequence of 5α-reductase inhibition and did not result in any known adverse events.

Tamsulosin.

Tamsulosin increases maximum urinary flow rate by reducing smooth muscle tension in the prostate and urethra, thereby relieving obstruction. It also improves the complex of irritative and obstructive symptoms in which bladder instability and tension of the smooth muscles of the lower urinary tract play an important role. Alpha-1 adrenergic blockers can reduce blood pressure by lowering peripheral resistance.
The tamsulosin hydrochloride (HCl) component in Dutatam 500/400 has not been shown to be bioequivalent to the tamsulosin HCl product currently available in Australia. The clinical efficacy of the two tamsulosin formulations has been shown to be similar. Due to differences in pharmacokinetics, small differences in some adverse event rates have been reported.
When the Australian formulation of tamsulosin (tamsulosin OCAS 0.4 mg) was compared to a tamsulosin formulation equivalent to dutasteride 500 microgram and tamsulosin hydrochloride 400 microgram modified release capsule (tamsulosin MR 0.4 mg), the incidences of all treatment emergent adverse events attributable to α₁-adrenergic blockade were 6.9% (non-cardiovascular 4.4% and cardiovascular 2.5%) for the OCAS formulation and 7.8% (non-cardiovascular 5.1% and cardiovascular 3.2%) for the MR formulation. Non-cardiovascular events included all abnormal ejaculation-related events, headache, asthenia, fatigue, somnolence, rhinitis, nasal dryness, nasal congestion and nasal obstruction. Cardiovascular events included all dizziness-related events, palpitations, tachycardia, hypotension, orthostatic hypotension, dizziness postural, syncope, orthostatic/ circulatory collapse and depressed level of/ loss of consciousness. The most common treatment emergent adverse events were dizziness (1.4% vs 1.3%) and retrograde ejaculation (1.7% vs 1.4%). If switching between tamsulosin formulations, patients should be advised of these differences and monitored accordingly. Patients should also be reminded to adhere to the dosage and administration requirements for each product.

Clinical trials.

Dutasteride co-administered with tamsulosin. The following statements reflect the information available on dutasteride and tamsulosin when administered together as separate medications.
Dutasteride 500 microgram/day (n = 1,623), tamsulosin 400 microgram/day (n = 1,611) or the combination of dutasteride 500 microgram plus tamsulosin 400 microgram (n = 1,610) administered once daily [total number of patients = 4844] were evaluated in men with moderate to severe symptoms of BPH who had prostate volumes ≥ 30 mL and Prostate Specific Antigen (PSA) values within the range 1.5-10 nanogram/mL in a multicenter, multinational, randomized double-blind, parallel group study (CombAT). Approximately 52% of subjects had previous exposure to 5-alpha-reductase inhibitor or alpha-blocker treatment.
The primary efficacy endpoint at 2 years of treatment was the level of improvement from baseline in the international prostate symptom score (IPSS).
The combination of dutasteride and tamsulosin provides superior improvement in symptoms than either component alone. After 2 years of treatment, co-administration therapy showed a statistically significant adjusted mean improvement in symptom scores from baseline of -6.2 units. The adjusted mean improvements in symptom scores observed with the individual therapies were -4.9 units for dutasteride and -4.3 units for tamsulosin.
The adjusted mean improvement in flow rate from baseline was 2.4 mL/sec for co-administration therapy, 1.9 mL/sec for dutasteride and 0.9 mL/sec for tamsulosin. The adjusted mean improvement in BPH Impact Index (BII) from baseline was -2.1 units for co-administration therapy, -1.7 units for dutasteride and -1.5 units for tamsulosin. These improvements in flow rate and BII were statistically significant for co-administration therapy compared to both monotherapies.
The reduction in total prostate volume and transition zone volume after 2 years of treatment was statistically significant for co-administration therapy compared to tamsulosin monotherapy alone. See Table 3.

The primary efficacy endpoint at 4 years of treatment was time to first event of AUR or BPH-related surgery. The study was powered to show a statistical difference between combination therapy and tamsulosin, but not between combination therapy and dutasteride or between tamsulosin and dutasteride. After 4 years of treatment, combination therapy significantly reduced the risk of AUR or BPH-related surgery (65.8% reduction in risk p < 0.001 [95% CI 54.7% to 74.1%]) compared to tamsulosin monotherapy. The incidence of AUR or BPH-related surgery by year 4 was 4.2% for combination therapy and 11.9% for tamsulosin (p < 0.001). Compared to dutasteride monotherapy, combination therapy reduced the risk of AUR or BPH-related surgery by 19.6%; the difference between treatment groups was not significant (p = 0.18 [95% CI: -10.9% to 41.7%]). The incidence of AUR or BPH-related surgery by year 4 was 4.2% for combination therapy and 5.2% for dutasteride.
Clinical progression was defined as a composite of worsening symptoms (IPSS), and BPH-related events of AUR, incontinence, UTI, and renal insufficiency. Combination therapy was associated with a statistically significantly lower rate of clinical progression compared with tamsulosin (p < 0.001, 44.1% risk reduction [95% CI: 33.6% to 53.0%]) after 4 years. The rates of clinical progression for combination therapy, tamsulosin, and dutasteride were: 12.6%, 21.5%, and 17.8%, respectively.
The statistically significant adjusted mean improvement in symptom scores (IPSS) from baseline was maintained from year 2 to year 4. The adjusted mean improvements in symptom scores observed were -6.3 units for combination therapy, -5.3 units for dutasteride monotherapy and -3.8 units for tamsulosin monotherapy.
After 4 years of treatment, the adjusted mean improvement in flow rate (Q_max) from baseline was 2.4 mL/sec for combination therapy, 2.0 mL/sec for dutasteride monotherapy and 0.7 mL/sec for tamsulosin monotherapy. Compared with tamsulosin, the adjusted mean improvement from baseline in Q_max was statistically significantly greater with combination therapy at each 6 month assessment from Month 6 to Month 48 (p < 0.001). Compared with dutasteride, the adjusted mean improvement from baseline in Q_max was not statistically significantly different than with combination therapy (p = 0.050 at Month 48).
Combination therapy was significantly superior (p < 0.001) to tamsulosin monotherapy and to dutasteride monotherapy for the improvement in health outcome parameters BII and BPH-related Health Status (BHS) at 4 years. The adjusted mean improvement in BII from baseline was -2.2 units for the combination, -1.8 units for dutasteride and -1.2 units for tamsulosin. The adjusted mean improvement in BHS from baseline was -1.5 units for the combination, -1.3 units for dutasteride and -1.1 units for tamsulosin.
The reduction in total prostate volume and transition zone volume after 4 years of treatment was statistically significant for combination therapy compared to tamsulosin monotherapy alone. See Table 4.

Dutasteride monotherapy. The efficacy and safety of dutasteride 500 microgram/day in the treatment and prevention of progression of BPH in 4325 males (aged 47 to 94 years with BPH who had enlarged prostates (greater than 30 mL) and a PSA value within the range 1.5-10 nanogram/mL) was demonstrated in three pivotal, randomised, double-blind, placebo-controlled, 2-year multicentre studies (ARIA3001, ARIA3002 and ARIB3003). Of the 4325 males enrolled in the studies, 2167 received dutasteride and 2158 received placebo.
Pooled data from the three pivotal studies show that, in men with BPH, dutasteride reduces the risk of both AUR and the need for surgical intervention (SI). Improvements in BPH-related symptoms, increased maximum urinary flow rates, and decreasing prostate volume suggest dutasteride reverses the progression of BPH in men with an enlarged prostate.
Pooled efficacy data from the three pivotal studies is summarised below:

Acute urinary retention (AUR) and surgical intervention.

Relative to placebo dutasteride significantly reduces both the risk and incidence of AUR by 57% (4.2% for placebo versus 1.8% for dutasteride) and the need for BPH-related surgical intervention by 48% (4.1% for placebo versus 2.2% for dutasteride) over 24 months. See Table 5.

Lower urinary tract symptoms (LUTS) assessed by AUA-SI.

Symptoms were quantified using the AUA-SI (American Urological Association Symptom Index), a seven-item questionnaire that evaluates urinary symptoms (incomplete emptying, frequency, intermittency, urgency, weak stream, straining, and nocturia) by rating on a 0 to 5 scale with a maximum score of 35. Entry criteria included a screening score of ≥ 12 (moderate to severe symptoms). A reduction in score signifies an improvement in symptoms.
The AUA-SI results at each of the scheduled visits, pooled across the three pivotal studies (ARIA3001, ARIA3002, and ARIB3003), are presented in Figure 1. The baseline AUA-SI score across the three studies was approximately 17 units in both treatment groups. Statistically significant improvements in symptom score in patients treated with dutasteride compared to placebo were noted from Month 6 through to Month 24 (p < 0.001). At Month 24, the mean decrease from baseline in AUA-SI symptom scores was -4.8 units for dutasteride and -2.4 units for placebo.

Maximum urinary flow (Q_max).

The Q_max results at each of the scheduled visits, pooled across the three pivotal studies (ARIA3001, ARIA3002, and ARIB3003), are presented in Figure 2. Baseline Q_max was approximately 10 mL/sec (normal Q_max ≥ 15 mL/sec) in both treatment groups across the three studies. Statistically significant improvement in Q_max in patients treated with dutasteride compared to placebo was noted from Month 1 through to Month 24. At Month 24, treatment urinary flow had improved by 0.8 mL/sec and 2.4 mL/sec in the placebo and dutasteride groups respectively.

Prostate volume.

In patients treated with dutasteride, prostate volume was shown to reduce as early as one month after initiation of treatment and reductions continued through to Month 24 (p < 0.001). Dutasteride led to a mean reduction of prostate volume of 23.6% (from 54.9 mL at baseline to 42.1 mL) at Month 12 compared with a mean reduction of 0.5% (from 54.0 mL to 53.7 mL) in the placebo group. At 24 months, dutasteride decreased prostate volume by 25.7% (from 54.9 mL at baseline to 41.2 mL) compared with an increase of 1.7% (from 54.0 cc to 54.1 cc) in the placebo group.
Pooled safety data from the three pivotal studies show that the adverse reaction profile of dutasteride (500 microgram/day for 24 months) was similar to that of placebo (see Section 4.8 Adverse Effects (Undesirable Effects)).
Tamsulosin monotherapy. Tamsulosin rapidly (from one week) increases maximum urinary flow rate by reducing smooth muscle tension in the prostate and urethra, thereby relieving obstruction. It also improves the complex of irritative and obstructive symptoms in which bladder instability and tension of the smooth muscles of the lower urinary tract play an important role.

Cardiac failure.

In a 4-year comparison of dutasteride co-administered with tamsulosin and dutasteride or tamsulosin monotherapy in men with BPH (the CombAT study), the incidence of the composite term cardiac failure in the combination group (14/1610, 0.9%) was higher than in either monotherapy group: dutasteride, 4/1623 (0.2%) and tamsulosin, 10/1611, (0.6%). The relative risk estimate for time to first cardiac failure event was 3.57 [95% CI: 1.17, 10.8] for combination treatment compared to dutasteride monotherapy and 1.36 [95% CI: 0.61, 3.07] compared to tamsulosin monotherapy. The reason for the observed imbalance is not known. There was no difference between treatment groups in incidence of overall cardiovascular events.
In REDUCE (a 4-year, double-blind, randomized parallel group study comparing dutasteride 500 microgram/day or placebo in men at increased risk of developing prostate cancer), there was a higher incidence of the composite term cardiac failure in subjects taking dutasteride (30/4105, 0.7%) versus placebo (16/4126, 0.4%) for a relative risk estimate for time to first cardiac failure event of 1.91 [95% CI: 1.04, 3.50]. In a post-hoc analysis of concomitant alpha blocker use (primarily tamsulosin, alfuzosin, doxazosin and terazosin), there was a higher incidence of the composite term cardiac failure in subjects taking dutasteride and an alpha blocker concomitantly (12/1152, 1.0%), compared to subjects not taking dutasteride and an alpha blocker concomitantly: dutasteride and no alpha blocker (18/2953, 0.6%), placebo and an alpha blocker (1/1399, < 0.1%), placebo and no alpha blocker (15/2727, 0.6%). The reason for the observed imbalance is not known. There was no difference between treatment groups in incidence of overall cardiovascular events. No causal relationship between dutasteride (alone or in combination with an alpha blocker) and cardiac failure has been established (see Section 4.4 Special Warnings and Precautions for Use).
Prostate cancer and high grade tumours. In a 4 year comparison of placebo and dutasteride in 8231 men aged 50 to 75, with a prior negative biopsy for prostate cancer and baseline PSA between 2.5 nanogram/mL and 10.0 nanogram/mL (the REDUCE study), 6706 subjects had prostate needle biopsy data available for analysis to determine Gleason scores. There were 1517 subjects diagnosed with prostate cancer in the study. The majority of biopsy detectable prostate cancers in both treatment groups were diagnosed as low grade (Gleason 5-6). There is no difference in the incidence of Gleason 7-10 cancers (p = 0.81).
There was a higher incidence of Gleason 8-10 prostate cancers in the dutasteride group (n = 29, 0.9%) compared to the placebo group (n = 19, 0.6%) (p = 0.15). In years 1-2, the number of subjects with Gleason 8-10 cancers was similar in the dutasteride group (n = 17, 0.5%) and the placebo group (n = 18, 0.5%). In years 3-4, more Gleason 8-10 cancers were diagnosed in the dutasteride group (n = 12, 0.5%) compared with the placebo group (n = 1, < 0.1%) (p = 0.0035). There are no data available on the effect of dutasteride beyond 4 years in men at risk of developing prostate cancer. The percentage of subjects diagnosed with Gleason 8-10 cancers was consistent across study time periods (years 1-2 and years 3-4) in the dutasteride group (0.5% in each time period), while in the placebo group, the percentage of subjects diagnosed with Gleason 8-10 cancers was lower during years 3-4 than in years 1-2 (< 0.1% versus 0.5%, respectively). In a 4 year BPH study (CombAT) where there were no protocol-mandated biopsies and all diagnoses of prostate cancer were based on for-cause biopsies, the rates of Gleason 8-10 cancer were (n = 8, 0.5%) for dutasteride, (n = 11, 0.7%) for tamsulosin and (n = 5, 0.3%) for combination therapy (see Section 4.4 Special Warnings and Precautions for Use).
The results of a retrospective epidemiological, population-based study (n = 174,895) in community practice settings based upon electronic health records show that the use of 5-ARIs to treat BPH/LUTS is not associated with an increased risk of prostate cancer mortality (hazard ratio adjusted for competing risks: 0.85, 95% CI 0.72, 1.01) when compared with the use of alpha-blockers. Similar results were reported in a retrospective epidemiological study (n = 13,892) using electronic health records of men with prostate cancer in the UK (adjusted hazard ratio for prostate cancer mortality for 5-ARI users versus non-users: 0.86; 95% CI 0.69, 1.06). A prospective cohort study, the Health Professional's Follow-up Study (n = 38,058), also found that 5-ARI use was not associated with fatal prostate cancer (adjusted HR: 0.99; 95% CI 0.58, 1.69). The relationship between dutasteride use and prostate cancer mortality is unclear.
Effects on prostate specific antigen (PSA) and prostate cancer detection. In the REDUCE study, a 4-year comparison of placebo and dutasteride in 8231 men aged 50 to 75, patients with a prior negative biopsy for prostate cancer and baseline PSA between 2.5 nanogram/mL and 10.0 nanogram/mL, dutasteride treatment caused a decrease in mean serum PSA by approximately 50% after six months of treatment with a large variability (standard deviation of 30%) among patients. The PSA suppression observed at six months was similar in men who did or who did not develop biopsy-detectable prostate cancer during the study (see Section 4.4 Special Warnings and Precautions for Use).
Breast neoplasia. In dutasteride BPH monotherapy clinical trials, providing 3374 patient years of exposure to dutasteride, there were 2 cases of male breast cancer reported in dutasteride-treated patients, one after 10 weeks and one after 11 months of treatment, and 1 case in a patient who received placebo. In subsequent clinical trials in BPH and 8231 men aged 50 to 75, with a prior negative biopsy for prostate cancer and baseline PSA between 2.5 nanogram/mL and 10.0 nanogram/mL providing 17,489 patient years exposure to dutasteride and 5027 patient years exposure to dutasteride and tamsulosin combination, there were no reported breast cancer cases in any of the treatment groups.
Two case control, epidemiological studies, one conducted in a US (n = 339 breast cancer cases and n = 6780 controls) and the other in a UK (n = 338 breast cancer cases and n = 3930 controls) healthcare database, showed no increase in the risk of developing male breast cancer with the use of 5-ARIs (see Section 4.4 Special Warnings and Precautions for Use). Results from the first study did not identify a positive association for male breast cancer (relative risk for ≥ 1 year of use before breast cancer diagnosis compared with < 1 year of use: 0.70: 95% CI 0.34, 1.45). In the second study, the estimated odds ratio for breast cancer associated with the use of 5-ARIs compared with non-use was 1.08: 95% CI 0.62, 1.87.
The relationship between long-term use of dutasteride and male breast cancer has not been established.

5.2 Pharmacokinetic Properties

Bioequivalence was demonstrated between dutasteride 500 microgram and tamsulosin hydrochloride 400 microgram modified release capsule and concomitant dosing with separate dutasteride and tamsulosin capsules. (The formulation of tamsulosin used in these studies is not bioequivalent to the tamsulosin HCl product currently available in Australia. However, the clinical efficacy of the two different tamsulosin formulations has been shown to be similar.)
The tamsulosin HCl component of Dutatam 500/400 consists of a multiunit pelletised preparation which has modified release properties. The individual pellets consist of a drug core and an outer coating layer which reduces the rate of dissolution of the drug.
The single dose bioequivalence study was performed in both the fasted and fed states. A 30% reduction in C_max was observed for the tamsulosin component of dutasteride-tamsulosin in the fed state compared to the fasted state. Food had no effect on AUC of tamsulosin.

Absorption.

Dutasteride.

Dutasteride is administered orally in solution as a soft gelatin capsule. Following administration of a single 500 microgram dose, peak serum concentrations of dutasteride occur within 1 to 3 hours. Absolute bioavailability in man is approximately 60% relative to a 2 hour intravenous infusion. The bioavailability of dutasteride is not affected by food.

Tamsulosin.

Tamsulosin hydrochloride is absorbed from the intestine and is almost completely bioavailable. Tamsulosin hydrochloride exhibits linear kinetics, following single and multiple dosing, with achievement of steady state concentrations by the fifth day of once-a-day dosing. The rate of absorption of tamsulosin hydrochloride is reduced by a recent meal. Uniformity of absorption can be promoted by the patient always taking tamsulosin hydrochloride approximately 30 minutes after the same meal each day.
As noted above, there are differences in the pharmacokinetics of dutasteride 500 microgram and tamsulosin hydrochloride 400 microgram modified release capsule and the current Australian tamsulosin formulation. Table 6 has been taken from published literature.

Distribution.

Dutasteride.

Pharmacokinetic data following single and repeat oral doses show that dutasteride has a large volume of distribution (300 to 500 L). Dutasteride is highly bound to plasma proteins (greater than 99.5%).
Following daily dosing, dutasteride serum concentrations achieve 65% of steady state concentration after one month and approximately 90% after three months. Steady state serum concentrations (C_ss) of approximately 40 nanogram/mL are achieved after six months of dosing 500 microgram once a day. Similarly to serum, dutasteride concentrations in semen achieved steady state at six months. After 52 weeks of therapy, semen dutasteride concentrations averaged 3.4 nanogram/mL (range 0.4 to 14 nanogram/mL). Dutasteride partitioning from serum into semen averaged 11.5%.

Tamsulosin.

The mean steady state apparent volume of distribution of tamsulosin hydrochloride after intravenous administration to ten healthy male adults was 16 L, which is suggestive of distribution into extracellular fluids in the body.
Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha-1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 nanogram/mL).

Metabolism.

Dutasteride.

Dutasteride is extensively metabolised in humans. While not all metabolic pathways have been identified, in vitro studies show that dutasteride is metabolised by the CYP3A4 isoenzyme to 2 minor mono-hydroxylated metabolites. Dutasteride is not metabolised in vitro by human cytochrome P450 isoenzymes CYP1A2, CY2A6, CYP2E1, CYP2C8, CYP2C9, CYP2C19, CYP2B6 and CYP2D6.
In human serum, following dosing to steady state, unchanged dutasteride, 3 major metabolites (4'-hydroxydutasteride, 1,2-dihydrodutasteride and 6-hydroxydutasteride), and 2 minor metabolites (6,4'-dihydroxydutasteride and 15-hydroxydutasteride), have been detected. In vitro, 4'-hydroxydutasteride and 1,2-dihydrodutasteride metabolites are much less potent than dutasteride against both isoforms of human 5α-reductase. The activity of 6β-hydroxydutasteride is comparable to that of dutasteride.

Tamsulosin.

There is no enantiomeric bioconversion from tamsulosin hydrochloride [R(-) isomer] to the S(+) isomer in humans. Tamsulosin hydrochloride is extensively metabolised by cytochrome P450 enzymes in the liver and less than 10% of the dose is excreted in urine unchanged. However, the pharmacokinetic profile of the metabolites in humans has not been established. In vitro results indicate that CYP3A4 and CYP2D6 are involved in metabolism of tamsulosin as well as some minor participation of other CYP isoenzymes. Inhibition of hepatic drug metabolizing enzymes may lead to increased exposure to tamsulosin (see Section 4.4 Special Warnings and Precautions for Use). The metabolites of tamsulosin hydrochloride undergo extensive conjugation to glucuronide or sulfate prior to renal excretion.

Excretion.

Dutasteride.

Dutasteride is extensively metabolised. Following oral dosing of dutasteride 500 microgram/day to steady state in humans, 1.0% to 15.4% (mean of 5.4%) of the administered dose is excreted as dutasteride in the faeces. The remainder is excreted in the faeces as 4 major metabolites comprising 39%, 21%, 7%, and 7% each of drug-related material and 6 minor metabolites (less than 5% each). Only trace amounts of unchanged dutasteride (less than 0.1% of the dose) are detected in human urine.
At low serum concentrations (less than 3 nanogram/mL), dutasteride is cleared rapidly by both the concentration-dependent and concentration-independent elimination pathways. Single doses of 5 mg or less showed evidence of rapid clearance and a short half-life of 3 to 9 days.
At serum concentrations greater than 3 nanogram/mL, dutasteride is cleared slowly (0.35 to 0.58 L/h) primarily by linear, non-saturable elimination with terminal half-life of 3 to 5 weeks. At therapeutic concentrations, the terminal half-life of dutasteride is 3 to 5 weeks, and following repeat dosing of 500 microgram/day, the slower clearance dominates and the total clearance is linear and concentration-independent. Serum concentrations remain detectable (greater than 0.1 nanogram/mL) for up to 4 to 6 months after discontinuation of treatment.

Tamsulosin.

Tamsulosin half-life is 5 to 7 hours following intravenous administration. Following the administration of dutasteride 500 microgram and tamsulosin hydrochloride 400 microgram modified release capsule, the tamsulosin half-life was reported to be 12 to 14 hours. Approximately 10% is excreted unchanged in urine.

Special populations.

No pharmacokinetic studies have been conducted on special patient populations for dutasteride-tamsulosin. The following statements reflect the information available on the individual components.
Elderly.

Dutasteride.

Dutasteride pharmacokinetics and pharmacodynamics were evaluated in 36 healthy male subjects between the ages of 24 and 87 years following administration of a single 5 mg dose of dutasteride. Exposure of dutasteride, represented by AUC and C_max values, was not statistically different when comparing age groups. Half-life was not statistically different when comparing the 50 to 69 year old group to the greater than 70 years old group, which encompasses the age of most men with BPH. No differences in drug effect as measured by DHT reduction were observed between age groups. Results indicated that no dutasteride dose adjustment based on age is necessary.

Tamsulosin.

Cross-study comparison of tamsulosin hydrochloride overall exposure (AUC) and half-life indicate that the pharmacokinetic disposition of tamsulosin hydrochloride may be slightly prolonged in elderly males compared to young, healthy male volunteers. Intrinsic clearance is independent of tamsulosin hydrochloride binding to AAG, but diminishes with age, resulting in a 40% overall higher exposure (AUC) in subjects of age 55 to 75 years compared to subjects of age 20 to 32 years.
Renal impairment.

Dutasteride.

The effect of renal impairment on dutasteride pharmacokinetics has not been studied. However, less than 0.1% of a steady-state 500 microgram dose of dutasteride is recovered in human urine, so no adjustment in dosage is anticipated for patients with renal impairment.

Tamsulosin.

The pharmacokinetics of tamsulosin hydrochloride have been compared in 6 subjects with mild-moderate (30 ≤ CL_cr < 70 mL/min/1.73 m²) or moderate-severe (10 ≤ CL_cr < 30 mL/min/1.73 m²) renal impairment and 6 normal subjects (CL_cr > 90 mL/min/1.73 m²). While a change in the overall plasma concentration of tamsulosin hydrochloride was observed as the result of altered binding to AAG, the unbound (active) concentration of tamsulosin hydrochloride, as well as the intrinsic clearance, remained relatively constant. Therefore, patients with renal impairment do not require an adjustment in tamsulosin hydrochloride capsules dosing. However, patients with end stage renal disease (CL_cr < 10 mL/min/1.73 m²) have not been studied.
Hepatic impairment.

Dutasteride.

The effect of hepatic impairment on dutasteride pharmacokinetics has not been studied. Because dutasteride is extensively metabolised, exposure could be higher in hepatically impaired patients.

Tamsulosin.

The pharmacokinetics of tamsulosin hydrochloride have been compared in 8 subjects with moderate hepatic dysfunction (Child-Pugh's classification: Grades A and B) and 8 normal subjects. While a change in the overall plasma concentration of tamsulosin hydrochloride was observed as the result of altered binding to AAG, the unbound (active) concentration of tamsulosin hydrochloride does not change significantly with only a modest (32%) change in intrinsic clearance of unbound tamsulosin hydrochloride. Therefore, patients with moderate hepatic dysfunction do not require an adjustment in tamsulosin hydrochloride dosage. Tamsulosin hydrochloride has not been studied in patients with severe hepatic dysfunction.
Children. Dutatam 500/400 is contraindicated for use in children.

5.3 Preclinical Safety Data

Genotoxicity.

Dutasteride and tamsulosin hydrochloride showed no evidence of genotoxicity in a wide range of in vitro and in vivo tests.

Carcinogenicity.

Dutasteride.

In a carcinogenicity study in rats, dutasteride produced an increase in benign interstitial cell tumours in the testis at the high dose (158-fold clinical exposure). However, the endocrine mechanisms believed to be involved in the production of interstitial cell hyperplasia and adenomas in the rat are not relevant to humans. There were no clinically relevant effects on tumour profile in a carcinogenicity study in mice.

Tamsulosin.

Oral (dietary) administration of tamsulosin for up to 2 years in rats and mice was associated with an increased incidence of pituitary adenoma, mammary gland hyperplasia, mammary gland fibroadenoma and (in mice only) mammary gland adenocarcinoma. These effects occurred at plasma tamsulosin concentrations (AUC) up to 10 times lower than those expected in men undergoing treatment with tamsulosin, but they were observed only in female animals and are probably due to the hyperprolactinaemic effect of tamsulosin. It is not known if tamsulosin elevates prolactin during prolonged administration in humans. The relevance for human risk of the findings of prolactin-mediated endocrine tumours in female rodents is unknown.

6 Pharmaceutical Particulars

6.1 List of Excipients

Dutatam 500/400 capsules also contain the inactive ingredients butylated hydroxytoluene, glyceryl caprylate, gelatin, glycerol, titanium dioxide, microcrystalline cellulose, methacrylic acid-ethyl acrylate copolymer (1:1), talc, triacetin, iron oxide yellow, hypromellose, carrageenan, potassium acetate, TekPrint SW-9008 Black Ink (ID: 2328).

6.2 Incompatibilities

Incompatibilities were either not assessed or not identified as part of the registration of this medicine.

6.3 Shelf Life

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

6.4 Special Precautions for Storage

Store below 25°C.

6.5 Nature and Contents of Container

Dutatam 500/400 capsules are available in HDPE bottle with a polypropylene child-resistant closure in a pack size containing 30 capsules.

6.6 Special Precautions for Disposal

In Australia, any unused medicine or waste material should be disposed of by taking to your local pharmacy.

6.7 Physicochemical Properties

Dutasteride.

Dutasteride is a white to pale yellow powder. It is practically insoluble in water, and soluble in organic solvents, dimethyl sulfoxide, acetone, methanol, ethanol and isopropanol.

Tamsulosin hydrochloride.

White or almost white crystalline powder. It is sparingly soluble in water, and slightly soluble in the following solvents: acetone, ethanol, ethyl acetate and methanol.

Chemical structure.

The pKa values for tamsulosin are as follows: pKa1 = 8.4 (secondary amine) and pKa2 = 10.7 (sulphonamide). The partition coefficient is clogP = 2.2 (calculated using Property Calculator 4.7).

Dutasteride.

Chemical name: N-[2,5-Bis(trifluoromethyl) phenyl]-3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide.
Molecular formula: C₂₇H₃₀F₆N₂O₂.

Tamsulosin hydrochloride.

Chemical name: (-)-(R)-5-[2-[[2-(2-ethoxyphenoxy) ethyl] amino]propyl]-2-methoxybenzenesulfonamide, monohydrochloride.
Molecular formula: C₂₀H₂₈N₂O₅S.HCl.

CAS number.

Dutasteride.

164656-23-9.

Tamsulosin hydrochloride.

106463-17-6.

7 Medicine Schedule (Poisons Standard)

Schedule 4 - Prescription Only Medicine.

Service Unavailable

Consumer medicine information

Dutatam 500/400

Dutasteride; Tamsulosin hydrochloride

Keep track of your medicines

BRAND INFORMATION